{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:06:02Z","timestamp":1791417962870,"version":"4.3.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1016\/j.semnephrol.2004.06.013","type":"journal-article","created":{"date-parts":[[2008,9,21]],"date-time":"2008-09-21T13:22:07Z","timestamp":1222003327000},"page":"456-459","source":"Crossref","is-referenced-by-count":38,"title":["Vitamin D analogs: Actions and role in the treatment of secondary hyperparathyroidism"],"prefix":"10.1016","volume":"24","author":[{"given":"Kevin J.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther A.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1016\/j.semnephrol.2004.06.013_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/ndt\/10.supp3.13","article-title":"Renal osteodystrophy","volume":"10","author":"Gonz\u00e1lez","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib2","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1046\/j.1523-1755.1999.07304.x","article-title":"Pathogenesis of secondary hyperparathyroidism","volume":"73","author":"Slatopolsky","year":"1999","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib3","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1053\/ajkd.2001.20740","article-title":"Role of phosphorus in the pathogenesis of secondary hyperparathyroidism","volume":"37","author":"Slatopolsky","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib4","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1172\/JCI112714","article-title":"Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat","volume":"78","author":"Silver","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib5","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1210\/endo-119-6-2864","article-title":"Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene","volume":"119","author":"Russell","year":"1986","journal-title":"Endocrinology"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib6","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1210\/endo-117-5-2114","article-title":"1,25-dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture","volume":"117","author":"Cantley","year":"1985","journal-title":"Endocrinology"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1210\/endo-125-2-935","article-title":"Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells","volume":"125","author":"Kremer","year":"1989","journal-title":"Endocrinology"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1056\/NEJM198908033210502","article-title":"Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure","volume":"321","author":"Andress","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib9","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1172\/JCI111639","article-title":"Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients","volume":"74","author":"Slatopolsky","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib10","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/ki.1994.223","article-title":"Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD","volume":"45","author":"Quarles","year":"1994","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0272-6386(12)80446-X","article-title":"Hyperphosphatemia","volume":"19","author":"Delmez","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1159\/000057470","article-title":"Vitamin D analogs","volume":"25","author":"Brown","year":"1999","journal-title":"Miner Electrolyte Metab"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0272-6386(95)90455-7","article-title":"A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia","volume":"26","author":"Slatopolsky","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib14","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V105980","article-title":"Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone","volume":"10","author":"Finch","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-6386(97)90571-0","article-title":"A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content","volume":"30","author":"Takahashi","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-a-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact PTH in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib17","first-page":"315","article-title":"A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease","volume":"56","author":"Lindberg","year":"2001","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib18","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1053\/ajkd.1998.v32.pm9808145","article-title":"Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2","volume":"32","author":"Martin","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib19","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","article-title":"Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients","volume":"40","author":"Coyne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib20","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients","volume":"38","author":"Sprague","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/oxfordjournals.jbchem.a124346","article-title":"The binding properties, with blood proteins, and tissue distribution of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a noncalcemic analogue of 1 alpha, 25-dihydroxyvitamin D3, in rats","volume":"115","author":"Kobayashi","year":"1994","journal-title":"J Biochem (Tokyo)"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3177\/jnsv.35.529","article-title":"Protein-binding properties of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a synthetic analogue of 1 alpha,25-dihydroxyvitamin D3","volume":"35","author":"Okano","year":"1989","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib24","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/endo-128-4-1687","article-title":"On the mechanisms for the selective action of vitamin D analogs","volume":"128","author":"Dusso","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib25","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1053\/ajkd.2003.50097","article-title":"Multicenter clinical trial of 22-oxa-1,25-dihydroxyvitamin D3 for chronic dialysis patients","volume":"41","author":"Yasuda","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"suppl 10","key":"10.1016\/j.semnephrol.2004.06.013_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ndt\/17.suppl_10.28","article-title":"Long-term effect of 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in haemodialysis patients. One-year administration study","volume":"17","author":"Akizawa","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib27","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/ndt\/gfg296","article-title":"In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)(2) vitamin D(3)","volume":"18","author":"Hirata","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1046\/j.1523-1755.1999.055003821.x","article-title":"22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure","volume":"55","author":"Monier-Faugere","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0272-6386(00)70198-3","article-title":"Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism","volume":"35","author":"Tsukamoto","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib30","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/004982599238425","article-title":"In vivo and in vitro pharmacokinetics and metabolism studies of 26,26,26,27,27,27-F6-1,25(OH)2 vitamin D3 (Falecalcitriol) in rat","volume":"29","author":"Komuro","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/ajkd.1998.v32.pm9708607","article-title":"Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism","volume":"32","author":"Akiba","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib32","doi-asserted-by":"crossref","first-page":"546","DOI":"10.5414\/CPP39546","article-title":"Alfacalcidol in the therapy of renal bone disease","volume":"39","author":"Ritzerfeld","year":"2001","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s002239900701","article-title":"Vitamin D and the D-hormones, alfacalcidol and calcitriol, as therapeutic agents for osteoporotic populations","volume":"65","author":"Avioli","year":"1999","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib34","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","article-title":"Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure","volume":"310","author":"Hamdy","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib35","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1681\/ASN.V561344","article-title":"A comparison of oral and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism","volume":"5","author":"Lee","year":"1994","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib36","first-page":"271","article-title":"Long-term experience of alfacalcidol in renal osteodystrophy","volume":"51","author":"Sharman","year":"1982","journal-title":"QJM"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib37","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3181\/00379727-178-42028","article-title":"1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat","volume":"178","author":"Sjoden","year":"1985","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib38","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/jn\/114.11.2043","article-title":"Antirachitic activity of 1 alpha-hydroxyergocalciferol and 1 alpha-hydroxycholecalciferol in rats","volume":"114","author":"Sjoden","year":"1984","journal-title":"J Nutr"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib39","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1210\/jc.83.6.2156","article-title":"Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans","volume":"83","author":"Mawer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib40","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/ajkd.2000.16193","article-title":"Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism","volume":"36","author":"Frazao","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2004.06.013_bib41","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0272-6386(01)80010-X","article-title":"Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism","volume":"37","author":"Maung","year":"2001","journal-title":"Am J Kidney Dis"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929504000968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929504000968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T23:11:00Z","timestamp":1631833860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929504000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["S0270929504000968"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2004.06.013","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}